Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has completed key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The company announced that the Phase 2 deployment expands the capabilities of its proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMOs). According to the company, this advancement positions Oncotelic to capitalize on the growing demand for automation and AI in pharmaceutical production. Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. The company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
The completion of Phase 2 objectives marks a significant milestone for Oncotelic, as it moves toward commercializing its AI-powered GMP manufacturing platform. This development could have far-reaching implications for the pharmaceutical industry, where automation and AI are increasingly seen as critical to improving efficiency, quality, and compliance in manufacturing. By integrating PDAOAI with robotic systems, Oncotelic aims to offer a comprehensive solution that addresses key challenges in sterile manufacturing, such as contamination control and batch record accuracy.
For more information, see the full press release at https://nnw.fm/j1n43 and the company’s newsroom at https://nnw.fm/OTLC.
